Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
04/25/2022 | Press release | Distributed by Public on 04/25/2022 14:17
Please select the service you want to use:
Smartlinks | Minerva SA | Finance | Stock Markets | Security Markets | Stock Markets | Security Markets | Company News | Top Company News | Shareholders | Shareholder Meeting | Business Announcement | Manufacturing | Food Industry | Public Companies | Meat Processing and Preserving Companies | Bolsa de Valores de São Paulo (B3) | Börse Berlin | OTC Markets | Bolsa Institucional de Valores (BIVA)
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact